Sound Income Strategies LLC Purchases 147,698 Shares of Sabra Healthcare REIT, Inc. $SBRA
Sound Income Strategies LLC increased its stake in Sabra Healthcare REIT (NASDAQ:SBRA) by 20.5% during the fourth quarter, purchasing 147,698 additional shares to own a total of 869,108 shares worth approximately $16.7 million. Despite the company missing recent quarterly EPS estimates and having a high payout ratio of 187.5%, analysts maintain a "Moderate Buy" consensus rating with an average target price of $22.00. Sabra Healthcare REIT, which pays a quarterly dividend of $0.30, saw its revenue increase by 16.2% year-over-year.
Sabra Healthcare REIT, Inc. (NASDAQ:SBRA) Given Average Recommendation of "Moderate Buy" by Brokerages
Ten brokerages have given Sabra Healthcare REIT (NASDAQ:SBRA) an average "Moderate Buy" recommendation, with an average 12-month target price of $22.00, and some firms have recently raised their price targets. Despite missing Q4 EPS estimates and having a high dividend payout ratio of 187.5%, the company saw 16.2% revenue growth and is heavily owned by institutional investors. Sabra Healthcare REIT, which acquires and operates net-lease healthcare properties, is trading around $19.86 with a market cap of $5.01 billion.
Vanguard disaggregates holdings; reports 0% in Sabra Health Care REIT (SBRA)
Vanguard has filed a Schedule 13G/A amendment for Sabra Health Care REIT (SBRA), reporting 0% beneficial ownership due to an internal realignment effective January 12, 2026. This realignment means certain Vanguard subsidiaries will now report their holdings separately. The filing clarifies that this change does not reflect a sale of shares but rather a restructuring of reporting in accordance with SEC Release No. 34-39538.
Sabra Health Care (SBRA) EVP sells 15,231 shares at $19.86
Jessica Flores, Executive VP & CAO of Sabra Health Care REIT, Inc. (SBRA), sold 15,231 shares of common stock on March 25, 2026, at a weighted average price of $19.86 per share. Following this transaction, she directly holds 71,709 shares, a figure that includes 25,527 stock units convertible to common stock. This insider trading activity is noted as having a moderate impact and negative sentiment.
Sabra Healthcare REIT (NASDAQ:SBRA) Price Target Raised to $22.00 at Wells Fargo & Company
Wells Fargo & Company has increased its price target for Sabra Healthcare REIT (NASDAQ:SBRA) from $21.00 to $22.00, maintaining an "overweight" rating and suggesting a 10.57% upside. This adjustment comes despite Sabra reporting an earnings miss of $0.11 EPS versus $0.37 expected, though revenue did rise 16.2% year-over-year. The company has set its FY2026 guidance at 1.550–1.590 EPS, exceeding analyst forecasts of around 1.45 EPS.
Nordea Investment Management AB Lowers Stake in Sabra Healthcare REIT, Inc. $SBRA
Nordea Investment Management AB significantly reduced its stake in Sabra Healthcare REIT, Inc. by 11.9% in Q4 2025, selling 65,080 shares and ending the quarter with 479,790 shares valued at approximately $9.05 million. This move comes as Sabra reported Q4 earnings that missed consensus estimates, although its FY2026 guidance surpassed analyst forecasts. Despite diverse institutional investor activity and a current dividend yield of 6.0%, Sabra Healthcare REIT maintains a "Moderate Buy" consensus rating from analysts, with a target price of $21.90.
Tudor Investment Corp ET AL Takes $7.58 Million Position in Sabra Healthcare REIT, Inc. $SBRA
Tudor Investment Corp ET AL has initiated a new position in Sabra Healthcare REIT (NASDAQ:SBRA) by purchasing over 406,000 shares valued at approximately $7.58 million. This investment comes as Sabra Healthcare REIT reported mixed Q3 earnings, missing EPS estimates but showing a 16.2% year-over-year revenue increase and offering a high dividend yield of 6.1%. Analyst ratings for the stock are generally positive, with a consensus of "Moderate Buy" and a target price of $21.90.
97,730 Shares in Sabra Healthcare REIT, Inc. $SBRA Acquired by Pensionfund PDN
Pensionfund PDN has acquired 97,730 shares of Sabra Healthcare REIT, Inc. (NASDAQ:SBRA) valued at approximately $1.85 million, making it their 24th largest holding. Despite missing EPS estimates, Sabra reported a 16.2% YoY revenue increase and provides a 6.1% dividend yield. The stock has a "Moderate Buy" consensus rating and a target price of $21.90.
JPMorgan Chase & Co. Has $66.90 Million Stock Position in Sabra Healthcare REIT, Inc. $SBRA
JPMorgan Chase & Co. has significantly increased its stake in Sabra Healthcare REIT, Inc. (NASDAQ:SBRA) by 33.7%, now holding 3,589,253 shares valued at approximately $66.90 million. This move comes despite Sabra Healthcare REIT missing its recent quarterly EPS expectations, though the company provided an optimistic FY2026 EPS guidance and maintains a high-yield quarterly dividend. The article also details other institutional investor activity, analyst ratings, and the company's recent financial performance and dividend announcement.
Sabra Health Care REIT, Inc. to Attend the 2026 NIC Spring Conference
Sabra Health Care REIT, Inc. announced that its Chair and CEO Rick Matros, Chief Investment Officer Darrin Smith, Senior Vice President of Investments Eliza Gozar, and other company representatives will attend the 2026 NIC Spring Conference from March 30 to April 1, 2026, in Nashville, Tennessee. The company is a Maryland corporation that operates as a self-administered, self-managed REIT focused on owning and investing in healthcare real estate across the United States and Canada. This announcement indicates their active participation in key industry events to foster growth and connections within the healthcare real estate sector.
Sabra Health Care REIT, Inc. to Attend the 2026 NIC Spring Conference
Sabra Health Care REIT, Inc. (Nasdaq: SBRA) announced that key leaders, including Chair and CEO Rick Matros and Chief Investment Officer Darrin Smith, will attend the 2026 NIC Spring Conference. The conference is scheduled for March 30 – April 1, 2026, at the Omni Nashville Hotel in Nashville, Tennessee. Sabra operates as a real estate investment trust specializing in healthcare properties across the United States and Canada.
Sabra Health Care REIT, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics
Sabra Health Care REIT, Inc. has seen a slight stock price decline but achieved a 22.30% return over the past year, outperforming the S&P 500. Technical indicators show a mixed outlook with both bullish and bearish signals, including strong year-to-date performance against the S&P 500. The company's resilience is highlighted by its impressive returns across various time frames.
Engineers Gate Sells $28M in Sabra Health Care REIT Shares - News and Statistics
Engineers Gate Manager LP has sold 1,513,777 shares of Sabra Health Care REIT, valued at approximately $28.06 million, according to an SEC filing from February 17. Following this transaction, Engineers Gate's stake in Sabra Health Care REIT is now valued at $86.07 million, representing 1.02% of the fund's 13F assets and removing it from their top five holdings. Sabra Health Care REIT specializes in owning various healthcare facilities and leasing them under long-term agreements.
Sabra Healthcare REIT (NASDAQ:SBRA) Stock Price Expected to Rise, Truist Financial Analyst Says
Truist Financial has raised its price target for Sabra Healthcare REIT (NASDAQ:SBRA) from $21.00 to $22.00, maintaining a "hold" rating and implying a 5.95% upside. Despite missing Q4 EPS estimates with $0.11 EPS against $0.37 consensus, Sabra's revenue increased by 16.2% year-over-year, and the company set a FY2026 EPS guidance of $1.55-$1.59. Analyst sentiment is mixed, with the stock currently holding a "Moderate Buy" rating and an average target price of $21.90 from several firms.
Engineers Gate Reduces Holdings in Sabra Health Care REIT Amid Investor Focus on Rental Revenue Patterns
Engineers Gate Manager LP has reduced its stake in Sabra Health Care REIT (NASDAQ:SBRA) by selling over 1.5 million shares valued at approximately $28.06 million on February 17, 2026. This transaction has adjusted Sabra Health Care REIT's position to 1.02% of Engineers Gate's 13F portfolio. The article highlights investor focus on rental revenue patterns and the financial health of skilled nursing, senior housing, and behavioral health operators, which significantly impact Sabra's cash flow reliability.
Truist raises Sabra Healthcare REIT price target to $22 on fundamentals
Truist Securities has increased its price target for Sabra Healthcare REIT (NASDAQ:SBRA) to $22 from $21, while maintaining a Hold rating. The firm notes Sabra's strong healthcare real estate fundamentals, improved investment yield spread, and 16 consecutive years of dividend payments. Despite a recent earnings per share miss, the company's revenue surpassed expectations, indicating potential upside in its senior housing portfolio occupancy.
Sabra Healthcare REIT, Inc. $SBRA Position Boosted by Bank of Montreal Can
Bank of Montreal (Can) increased its stake in Sabra Healthcare REIT (NASDAQ:SBRA) by 8.2% in the third quarter, owning 2,787,655 shares valued at $51.96 million. Despite missing quarterly EPS estimates, Sabra's revenue grew 16.2% year-over-year, and the company announced a quarterly dividend of $0.30 per share, representing a 5.8% yield. Analysts maintain a "Moderate Buy" consensus rating with a target price of $21.80.
Schroder Investment Management Group Grows Holdings in Sabra Healthcare REIT, Inc. $SBRA
Schroder Investment Management Group significantly increased its stake in Sabra Healthcare REIT, Inc. (NASDAQ:SBRA) by 37.8%, now owning 1,994,739 shares valued at approximately $37.1 million. This comes despite Sabra reporting an earnings per share miss and having an elevated dividend payout ratio of 187.5%. The REIT maintains a "Moderate Buy" consensus rating from analysts with a target price of $21.80.
Duff & Phelps Investment Management Co. Cuts Holdings in Sabra Healthcare REIT, Inc. $SBRA
Duff & Phelps Investment Management Co. decreased its stake in Sabra Healthcare REIT, Inc. (NASDAQ:SBRA) by 3.0% in the third quarter, selling 76,450 shares. Despite this reduction, Duff & Phelps still holds 2,472,988 shares valued at $46.096 million. Other institutional investors showed mixed activity, with some increasing their positions and others reducing them, while analysts currently rate SBRA as a "Moderate Buy" with a consensus price target of $21.80.
Sabra Healthcare REIT, Inc. $SBRA Shares Purchased by Barclays PLC
Barclays PLC significantly increased its stake in Sabra Healthcare REIT, Inc. (NASDAQ:SBRA) by 116.2% in the third quarter, acquiring an additional 766,740 shares. This move boosted Barclays' total holdings to 1,426,718 shares, valued at approximately $26.59 million. Other institutional investors also modified their positions in SBRA, with the stock currently trading at $20.65, after declaring a quarterly dividend of $0.30 per share.
Sabra Health Care REIT, Inc. to Participate in Deutsche Bank’s 2026 Healthcare REIT Summit
Sabra Health Care REIT, Inc. announced that key executives, including its Chair and CEO Rick Matros, CFO Michael Costa, CIO Darrin Smith, and EVP of Finance Lukas Hartwich, will participate virtually in Deutsche Bank’s 2026 Healthcare REIT Summit on March 24, 2026. Sabra Health Care REIT is a Maryland corporation that invests in and owns real estate serving the healthcare industry across the United States and Canada. The company (Nasdaq: SBRA) shared this information via a press release from Business Wire.
Sabra Health Care CEO, CFO, CIO join Deutsche Bank virtual summit Mar. 24
Sabra Health Care REIT, Inc. (Nasdaq: SBRA) announced that its CEO, CFO, CIO, and EVP of Finance will participate virtually in Deutsche Bank's 2026 Healthcare REIT Summit on March 24, 2026. The company operates as a self-administered, self-managed real estate investment trust focused on the healthcare industry in the United States and Canada. This participation highlights Sabra's engagement with the investment community regarding its financial and strategic outlook.
Sabra Health Care REIT, Inc. to Participate in Deutsche Bank’s 2026 Healthcare REIT Summit
Sabra Health Care REIT, Inc. (Nasdaq: SBRA) announced that its key executives, including Rick Matros (Chair and CEO), Michael Costa (CFO), Darrin Smith (CIO), and Lukas Hartwich (EVP of Finance), will participate virtually in Deutsche Bank's 2026 Healthcare REIT Summit on March 24, 2026. The company operates as a self-administered real estate investment trust focused on the healthcare industry across the United States and Canada.
Victory Capital Management Inc. Buys 124,207 Shares of Sabra Healthcare REIT, Inc. $SBRA
Victory Capital Management Inc. increased its stake in Sabra Healthcare REIT, Inc. by 8.2%, purchasing 124,207 additional shares to own a total of 1,640,821 shares valued at approximately $30.6 million. Despite missing quarterly EPS estimates, Sabra Healthcare REIT reported a 16.2% year-over-year revenue increase and has an annualized dividend yield of 5.9%. Analysts currently hold a "Moderate Buy" consensus rating for the stock, with an average target price of $21.80.
Sabra Healthcare REIT, Inc. (NASDAQ:SBRA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Sabra Healthcare REIT, Inc. (NASDAQ:SBRA) has received a "Moderate Buy" consensus recommendation from brokerages, with five analysts rating it a buy and five a hold. The average 12-month price target is $21.80, and the company recently reported quarterly EPS of $0.11, missing analyst estimates, while revenue increased by 16.2% year-over-year. Sabra Healthcare REIT also declared a quarterly dividend of $0.30 per share, representing an annualized yield of 5.9%.
Sabra Health Care REIT, Inc. Experiences Evaluation Revision Amid Mixed Market Signals
Sabra Health Care REIT, Inc. has revised its evaluation due to current market dynamics, with its stock priced at $20.02 and a 17.14% return over the past year, underperforming the S&P 500. While some technical indicators show bullish sentiment, a mildly bearish trend is visible on monthly charts, reflecting mixed signals. The company outperformed the S&P 500 over the last month but has lagged over longer three and five-year periods.
Sabra Health Care REIT (SBRA) EVP granted dividend-equivalent stock units
Sabra Health Care REIT (SBRA) Executive VP & CAO Jessica Flores was granted 368 dividend-equivalent stock units on February 27, 2026. These units, valued at $0.00 per share, are part of the company’s 2009 Performance Incentive Plan and vest on the same schedule as original awards. Following this transaction, Flores directly holds 86,940 shares/units, including 25,527 stock units convertible to common shares.
[Form 4] Sabra Health Care REIT, Inc. Insider Trading Activity
Sabra Health Care REIT, Inc. Executive VP, CFO & Treasurer Michael Lourenco reported an acquisition of 4,005 shares of common stock on February 27, 2026. These shares are dividend equivalent payments on previously granted stock units and will vest on the same schedule as the related awards. Following this transaction, Lourenco directly holds 461,521 shares, including 278,415 stock units, and has indirect holdings through IRAs.
Director at Sabra Health Care REIT (SBRA) receives 781 stock units award
Catherine Cusack, a director at Sabra Health Care REIT, Inc. (SBRA), was granted 781 stock units as dividend equivalent payments on her previously awarded stock units. This non-cash transaction, recorded in a Form 4 SEC filing, increased her direct holdings to 72,929 stock units and shares, comprising both vested and unvested units. These new units will vest under the same terms as the original awards under the company's 2009 Performance Incentive Plan.
Sabra Health Care REIT (SBRA) CEO awarded 13,358 stock units
Sabra Health Care REIT's Chair, CEO, and President, Richard K. Matros, was granted 13,358 common stock units on February 27, 2026, as dividend equivalent payments on previously awarded stock units. These units, which have no purchase price, will vest and be paid in common stock shares on the same schedule as the original awards. Following this transaction, Matros directly holds 928,398 common shares and indirectly holds 1,857,686 shares through a revocable trust.
Sabra Healthcare REIT (NASDAQ:SBRA) Price Target Raised to $21.00
Scotiabank raised its price target for Sabra Healthcare REIT (NASDAQ:SBRA) from $20.00 to $21.00, reflecting a "sector perform" rating and a potential upside of 1.98%. Other analysts also increased their price targets to $21.00 or $22.00, resulting in a consensus "Moderate Buy" rating with a target of $21.80, despite the company missing EPS expectations last quarter but providing stronger-than-analyst guidance for FY2026. Institutional investors show high ownership at 99.4%, with several hedge funds increasing their stakes.
Sabra Health Care: Leveraging SHOP To Capture Silver Tsunami Tailwinds (NASDAQ:SBRA)
Sabra Health Care (SBRA) is rated a Buy due to its strong SHOP expansion, robust guidance, and sustainable 5.84% dividend yield. The company projects 4.9%-5.4% FFO growth and plans significant investments in 2026, supported by a solid pipeline and debt management. While the transition to SHOP increases potential volatility, it also offers upside from demographic trends, balanced by favorable long-term industry dynamics.
Sabra Healthcare REIT stock hits 52-week high at 20.71 USD By Investing.com
Sabra Healthcare REIT (SBRA) recently hit a 52-week high of $20.71, reflecting a strong performance with a 34% total return over the past 12 months. InvestingPro analysis suggests the stock is slightly undervalued, boasting a $5.2 billion market cap and a 5.84% dividend yield, part of a 16-year dividend payment streak. Despite a recent EPS miss in Q4 2025, the company exceeded revenue expectations, indicating resilience in its financial performance.
Does Sabra’s 2026 Earnings Outlook and Triple-Net Cash NOI Guidance Change The Bull Case For SBRA?
Sabra Health Care REIT reported its Q4 2025 results and full-year 2025 figures, including revenue of US$211.90 million and net income of US$27.23 million for the quarter, and US$774.63 million and US$155.61 million respectively for the year. The company also provided 2026 earnings guidance of US$0.60–US$0.64 in net income per diluted share, anchored by projected low-single-digit triple-net Cash NOI growth. This guidance maintains focus on execution risk and operator performance, while the stable US$0.30 quarterly dividend highlights the importance of Cash NOI resilience and tenant health for investors.
Sabra Healthcare REIT stock hits 52-week high at 20.71 USD
Sabra Healthcare REIT (SBRA) recently hit a 52-week high of $20.71, marking a 34% total return over the past year. Investing.com analysis suggests the stock is slightly undervalued, supported by a healthy 5.84% dividend yield and a 16-year streak of consecutive dividend payments. While the company recently missed its EPS forecast for Q4 2025, it exceeded revenue expectations, indicating mixed financial performance.
Sabra Health Care REIT Hits New 52-Week High at $20.88
Sabra Health Care REIT, Inc. has reached a new 52-week high of $20.88, marking a 48.26% increase over the past year and outperforming the S&P 500. The company has a market capitalization of $5,025 million, a P/E ratio of 24.00, and a significant dividend yield of 552.13%. This milestone highlights strong performance in the realty sector, making it an appealing prospect for income-focused investors.
Sabra Healthcare REIT (NASDAQ:SBRA) Hits New 12-Month High - Here's What Happened
Sabra Healthcare REIT (NASDAQ:SBRA) shares reached a new 52-week high of $20.73 on Thursday, with analysts setting an average price target of $21.70 and a "Moderate Buy" rating. Despite an EPS miss, the company reported revenue in line with expectations, provided FY2026 guidance, and declared a quarterly dividend of $0.30 per share. Institutional investors have also significantly increased their holdings in SBRA.
Does Sabra’s 2026 Earnings Outlook and Triple-Net Cash NOI Guidance Change The Bull Case For SBRA?
Sabra Health Care REIT reported its fourth quarter 2025 results, with sales of US$92.92 million and net income of US$27.23 million, and issued 2026 earnings guidance of US$0.60–US$0.64 in net income per diluted share. This guidance suggests low-single-digit triple-net Cash NOI growth, which will influence its investment narrative. The article discusses how this guidance, along with a maintained quarterly dividend of US$0.30 per share, reshapes the outlook for SBRA, emphasizing the importance of operator performance and the portfolio transition.
JPMorgan Chase & Co. Boosts Stock Position in Sabra Healthcare REIT, Inc. $SBRA
JPMorgan Chase & Co. significantly increased its stake in Sabra Healthcare REIT, Inc. (NASDAQ:SBRA) by 33.7% in the third quarter, holding over 3.5 million shares valued at approximately $66.9 million. Despite Sabra Healthcare REIT missing Q4 earnings expectations ($0.11 EPS vs. $0.37 expected) and reporting $201.35 million in revenue, the company has declared a quarterly dividend of $0.30 per share, leading to an annualized yield of 5.9%. Analysts currently have a "Moderate Buy" consensus rating for SBRA with an average target price of $21.70, while institutional investors and hedge funds collectively own 99.40% of the company's stock.
Greenland Capital Management LP Makes New $4.19 Million Investment in Sabra Healthcare REIT, Inc. $SBRA
Greenland Capital Management LP has made a new $4.19 million investment in Sabra Healthcare REIT, acquiring 225,000 shares in the third quarter. This investment, representing 0.09% of the company, comes as Sabra Healthcare REIT faces a mixed financial outlook, having missed quarterly EPS estimates but showing a 16.2% year-over-year revenue increase. The company also announced a quarterly dividend of $0.30, yielding 5.9%, despite a high payout ratio of 187.5% and a "Moderate Buy" consensus from analysts.
Rhumbline Advisers Sells 50,284 Shares of Sabra Healthcare REIT, Inc. $SBRA
Rhumbline Advisers reduced its stake in Sabra Healthcare REIT, Inc. (NASDAQ:SBRA) by 5.8% in the Q3, selling 50,284 shares and now owning 824,077 shares worth $15.36 million. Other institutional investors like Cornerstone Wealth Management LLC and AlphaQuest LLC significantly increased their positions in the company during the same period. Analyst ratings for SBRA currently average a "Moderate Buy" with a target price of $21.60, despite mixed recommendations from various firms.
Sabra Healthcare REIT (NASDAQ:SBRA) Given New $23.00 Price Target at Citizens Jmp
Citizens Jmp has increased its price target for Sabra Healthcare REIT (NASDAQ:SBRA) to $23.00 from $22.00, maintaining a "market outperform" rating and suggesting an 11.8% upside. This follows Sabra's Q1 earnings miss, although revenue was in line with expectations, and the company issued FY2026 guidance above analyst estimates. Analyst coverage for SBRA is mixed, with five "Buy" and five "Hold" ratings, and a consensus price target of $21.33.
Earnings call transcript: Sabra Healthcare REIT misses EPS forecast in Q4 2025
Sabra Healthcare REIT (SBRA) reported Q4 2025 earnings with a 35.29% EPS miss at $0.11 against an expected $0.17, though revenue surpassed forecasts by 7.59% reaching $211.9 million. Despite the EPS miss, the stock saw a slight pre-market increase, reflecting cautious optimism. The company provided 2026 guidance, projecting normalized FFO per share between $1.49 and $1.53, emphasizing strategic growth in its senior housing portfolio.
Sabra Health Care REIT ‘off to strong start,’ with 92 percent of $240M in upcoming deals in senior living
Sabra Health Care REIT has had a strong start to the year with $240 million in investment deals, 92% of which are in senior living. The company expects to exceed its 2025 investment volume of $450 million and is focusing on expanding its managed senior housing operating portfolio. Occupancy and margins in Sabra's senior housing portfolios continue to trend positively, especially in Canada.
Analysts Are Neutral on Top Real Estate Stocks: Sabra Healthcare REIT (SBRA), Public Storage (PSA)
Analysts have issued neutral ratings for Sabra Healthcare REIT (SBRA) and Public Storage (PSA), indicating neither bullish nor bearish sentiment. Truist Financial maintained a Hold rating on Sabra Healthcare REIT with a $21.00 average price target, while Mizuho Securities reiterated a Hold rating on Public Storage with a $299.91 average price target. The reports suggest a consensus of holding these stocks rather than actively buying or selling, despite projected slight upsides.
Sabra Healthcare REIT Q1 2026 slides: Targeting 5% FFO growth with diversified portfolio
Sabra Healthcare REIT (NASDAQ: SBRA) presented its Q1 2026 investor slides, projecting approximately 5% year-over-year FFO and AFFO growth. Despite a Q4 2025 EPS miss, the company's diversified portfolio, focus on demographic trends, and strong balance sheet position it for future growth in the healthcare real estate market. Sabra emphasized its strategic alignment with operators providing compassionate care and highlighted favorable supply-demand dynamics in the skilled nursing sector.
Sabra Healthcare REIT Q1 2026 slides: Targeting 5% FFO growth with diversified portfolio
Sabra Healthcare REIT (NASDAQ:SBRA) released its Q1 2026 investor presentation, projecting a 5% year-over-year growth in normalized FFO and AFFO, despite a Q4 2025 EPS miss. The company emphasizes its diversified portfolio of 393 investments, strategic focus on favorable demographic trends like the growing elderly population, and disciplined balance sheet management. Sabra aims to capitalize on supply constraints in senior housing and skilled nursing, positioning itself for continued growth in the healthcare real estate market.
Sabra Health Care REIT, Inc. (SBRA) Shares Steady as Managed Senior Housing Drives 2025 Growth
Sabra Health Care REIT, Inc. (SBRA) saw its shares rise after reporting strong fourth-quarter and full-year 2025 results, driven by significant growth in its managed senior housing portfolio. The company provided optimistic 2026 guidance, expecting continued strong performance in net income and FFO. Despite facing sector-wide challenges like labor shortages and government reimbursement policies, Sabra's diversified portfolio and strategic investments position it for future growth amidst aging demographics.
Sabra Health Care REIT, Inc. (SBRA) Shares Steady as Managed Senior Housing Drives 2025 Growth
Sabra Health Care REIT, Inc. (SBRA) saw its shares rise by 1.22% following the release of its Q4 and full-year 2025 results, with the stock trading near its 52-week high. The company announced 2026 guidance and highlighted record growth in its managed senior housing portfolio, despite ongoing challenges from labor shortages and government reimbursement policies. Sabra's strategic focus on managed senior housing and its solid investment activity contributed to its financial performance and positive outlook.
Why Sabra Health Care REIT (SBRA) Is Up 5.6% After 2025 Results And 2026 Earnings Guidance
Sabra Health Care REIT's stock rose 5.6% following the release of its 2025 full-year results and 2026 earnings guidance. The company reported full-year revenue of US$774.63 million and net income of US$155.61 million, and reaffirmed its quarterly dividend of US$0.30 per share. Investors are keenly watching tenant performance and dividend sustainability, especially given the high payout ratio.
